Premium
Anti‐Helicobacter pylori Antibody Profiles in Epstein‐Barr virus (EBV)‐Positive and EBV‐Negative Gastric Cancer
Author(s) -
Camargo M. Constanza,
Kim KyoungMee,
Matsuo Keitaro,
Torres Javier,
Liao Linda M.,
Morgan Douglas R.,
Michel Angelika,
Waterboer Tim,
Zabaleta Jovanny,
Dominguez Ricardo L.,
Yatabe Yasushi,
Kim Sung,
RochaGuevara Erick R.,
Lissowska Jolanta,
Pawlita Michael,
Rabkin Charles S.
Publication year - 2016
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12249
Subject(s) - helicobacter pylori , epstein–barr virus , cancer , virus , antibody , virology , medicine , helicobacter , immunology , gastroenterology
Background Helicobacter pylori is the primary cause of gastric cancer, but about 9% of cases harbor Epstein–Barr virus ( EBV ) in the tumor cells. There is limited evidence on the possible interaction or antagonism between these infectious agents in gastric carcinogenesis. Methods We compared H. pylori serologic profiles of EBV ‐positive (n = 58) and EBV ‐negative (n = 111) noncardia gastric cancer patients from the United States National Cancer Institute's International EBV ‐Gastric Cancer Consortium. EBV positivity of tumors was assessed by in situ hybridization. Serum levels of 15 antibodies to immunogenic proteins of H. pylori (Cad, CagA, Cagδ, CagM, Catalase, Gro EL , HcpC, HP 0231, HP 0305, HpaA, HyuA, NapA, Omp, UreA, VacA) were assessed using bead‐based multiplex serology. Logistic regression models were used to adjust odds ratios ( OR ) for country, age, sex, and year of diagnosis. Results Seropositivity to individual proteins ranged up to 90% overall. Antibodies to Catalase were borderline associated with tumor EBV positivity (adjusted OR = 3.15, p = .0024, Bonferroni corrected p = .036). Distributions of other antibodies did not vary by tumor EBV status. Conclusion Similarity of host–response indicates the essential etiological role of H. pylori in EBV ‐positive gastric cancer.